News

METRO-PD1: A Phase I Feasibility Study Evaluating Anti-PD1 (NIVOLUMAB) In Combination With Metronomic Chemotherapy In Children And Teenagers With Refractory/Relapsing Solid Tumors Or Lymphoma

Presented at SIOP 2021 Congress

8 November 2021

The Anticancer Fund is participating in the World Cancer Series organised by The Economist

2 November 2021

Our good cause My Cancer Navigator now supported by Belfius

29 October 2021

Drug repurposing candidates in the treatment of brain metastases

Presented during the 10th edition of Brain Metastases Research and Emerging Therapy Conference

30 September 2021

10 drugs in 1 trial: an unconventional way to fight brain cancer

7 September 2021

A publication by scientists of the Anticancer Fund

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3

Marc-Eric Halatsch, Richard E. Kast, Georg Karpel-Massler, Benjamin Mayer, Oliver Zolk, Bernd Schmitz, Angelika Scheuerle, Ludwig Maier, Lars Bullinger, Regine Mayer-Steinacker, Carl Schmidt, Katharina Zeiler, Ziad Elshaer, Patricia Panther, Birgit Schmelzle, Anke Hallmen, Annika Dwucet, Markus D. Siegelin, Mike-Andrew Westhoff, Kristine Beckers, Gauthier Bouche, and Tim Heiland. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neuro-Oncology Advances, 3(1), 1–11, 2021, doi.org/10.1093/noajnl/vdab075

6 September 2021